Skip to product information
1 of 1

Elabscience

SKU:E-AB-F1140D-200Tests

PE Anti-Human CD27 Antibody[O323]

PE Anti-Human CD27 Antibody[O323]

Regular price $200.00 USD
Regular price Sale price $200.00 USD
Sale Sold out
Shipping calculated at checkout.
Size

PE Anti-Human CD27 Antibody[O323]

The PE Anti-Human CD27 Antibody [O323] is a highly specific and reliable tool designed for the detection and analysis of CD27 expression in human samples. This antibody is conjugated with phycoerythrin (PE), a fluorescent dye that allows for easy visualization and quantification of CD27-positive cells.

CD27 is a transmembrane protein belonging to the tumor necrosis factor receptor superfamily. It is primarily expressed on the surface of T cells, B cells, and natural killer cells, playing a crucial role in their activation and differentiation. The PE Anti-Human CD27 Antibody [O323] recognizes the extracellular domain of CD27, enabling precise identification and characterization of CD27-expressing cells.

This antibody has been extensively validated and exhibits exceptional sensitivity and specificity in various applications, including flow cytometry and immunofluorescence. It offers excellent staining intensity and low background noise, ensuring accurate and reliable results. The PE conjugation provides bright and distinct signals, facilitating the discrimination of CD27-positive cells from the negative population.

The PE Anti-Human CD27 Antibody [O323] is supplied in a ready-to-use format, eliminating the need for additional reagents or preparation steps. It is suitable for use in both research and clinical settings, enabling the investigation of CD27 expression in various diseases and immune responses.

In summary, the PE Anti-Human CD27 Antibody [O323] is a high-quality and efficient tool for the detection and analysis of CD27 expression in human samples. Its exceptional sensitivity, specificity, and ease of use make it an invaluable asset for researchers and clinicians studying immune cell activation and differentiation.

View full details